We regret to inform you that Bristol Myers Squibb (BMS) has made the difficult decision to discontinue the production and supply of COUMADIN (warfarin sodium) in Canada, the United States, Latin America, and Saudi Arabia, due to an unexpected manufacturing issue that could not be resolved expeditiously, despite important efforts.
 
Healthcare providers will need to contact patients who have been prescribed COUMADIN regarding alternative therapeutic options. We sincerely empathize with patients who will be required to switch to an alternative therapy. We also recognize the burden placed on the healthcare system during this difficult time.

• For more information for healthcare professionals, click here.